<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189904</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-010</org_study_id>
    <secondary_id>HHSN266200400072C</secondary_id>
    <nct_id>NCT00189904</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients</brief_title>
  <official_title>A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts &gt;350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bavarian Nordic</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to gather information on the safety and immunogenicity of an&#xD;
      investigational smallpox vaccine in HIV infected populations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence, relationship and intensity of any serious and/or unexpected adverse reaction at any time during the study</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralisation assay specific seroconversion rates and geometric mean titres (at all blood sampling time points)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points)</measure>
  </secondary_outcome>
  <enrollment type="Actual">151</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE (MVA-BN)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male subjects between 18 and 49 years of age or female subjects between 18 and 55&#xD;
             years of age who provided informed consent.&#xD;
&#xD;
          -  Women with negative pregnancy test.&#xD;
&#xD;
          -  Women of childbearing potential must use an acceptable method of contraception.&#xD;
&#xD;
          -  Cardiac enzymes within ULN.&#xD;
&#xD;
          -  White blood cells ≥ 2500/mm3 and &lt; 11,000/ mm3.&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1000/mm3.&#xD;
&#xD;
          -  Adequate renal function.&#xD;
&#xD;
          -  Adequate hepatic function.&#xD;
&#xD;
          -  Negative hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc).&#xD;
&#xD;
          -  Negative antibody test to hepatitis C virus (HCV).&#xD;
&#xD;
          -  Negative urine glucose by dipstick or urinalysis.&#xD;
&#xD;
          -  Normal 12-lead electrocardiogram.&#xD;
&#xD;
          -  Availability for follow-up during the study.&#xD;
&#xD;
        Groups 1 and 3 (All vaccinia-naïve subjects) additionally:&#xD;
&#xD;
          -  No history of known or suspected previous smallpox vaccination.&#xD;
&#xD;
          -  No detectable vaccinia scar.&#xD;
&#xD;
          -  No military service prior to 1989 or after January 2003.&#xD;
&#xD;
        Groups 2 and 4 (All previously vaccinated subjects) additionally:&#xD;
&#xD;
          -  History of at least one previous smallpox vaccination&#xD;
&#xD;
          -  Time since most current smallpox vaccination &gt; 10 years.&#xD;
&#xD;
        Groups 1 and 2 (All HIV Infected subjects) additionally:&#xD;
&#xD;
          -  Documented HIV-1 infection&#xD;
&#xD;
          -  Plasma HIV-1 RNA level &lt; 400 copies/mL at screening.&#xD;
&#xD;
          -  CD4 cells ≥ 350/µL&#xD;
&#xD;
          -  Haemoglobin ≥ 9.0 g/dL.&#xD;
&#xD;
          -  Platelets ≥ 100,000/mm3.&#xD;
&#xD;
          -  AST (SGOT), ALT (SGPT) and alkaline phosphatase ≤ 3 x ULN&#xD;
&#xD;
        Groups 3 and 4 (All Healthy subjects) additionally:&#xD;
&#xD;
          -  Negative ELISA for HIV.&#xD;
&#xD;
          -  Haemoglobin &gt;11 g/dL.&#xD;
&#xD;
          -  Platelets ≥ 140,000/mm3.&#xD;
&#xD;
          -  AST (SGOT), ALT (SGPT) and alkaline phosphatase without clinically significant&#xD;
             findings&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Uncontrolled serious infection i.e. not responding to antimicrobial therapy.&#xD;
&#xD;
          -  History of any serious medical condition (other than HIV infection).&#xD;
&#xD;
          -  History of or active autoimmune disease.&#xD;
&#xD;
          -  Known or suspected impairment of immunologic function (other than HIV infection).&#xD;
&#xD;
          -  History of malignancy.&#xD;
&#xD;
          -  History or clinical manifestation of clinically significant and severe haematological,&#xD;
             renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal&#xD;
             disorders.&#xD;
&#xD;
          -  Clinically significant mental disorder not adequately controlled by medical treatment.&#xD;
&#xD;
          -  Any condition which might interfere with study objectives.&#xD;
&#xD;
          -  History of coronary heart disease, myocardial infarction, angina, congestive heart&#xD;
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood&#xD;
             pressure, or any other heart condition under the care of a doctor.&#xD;
&#xD;
          -  History of an immediate family member with onset of ischemic heart disease before age&#xD;
             50.&#xD;
&#xD;
          -  Ten percent or greater risk of developing a myocardial infarction or coronary death&#xD;
             within the next 10 years using the National Cholesterol Education Program's risk&#xD;
             assessment tool.&#xD;
&#xD;
          -  History of chronic alcohol abuse and/or intravenous drug abuse.&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine.&#xD;
&#xD;
          -  Known previous allergic reaction to immunoglobulins.&#xD;
&#xD;
          -  Known allergies to cidofovir or probenecid.&#xD;
&#xD;
          -  History of anaphylaxis or severe allergic reaction.&#xD;
&#xD;
          -  Acute disease (illness with or without a fever) at the time of enrollment.&#xD;
&#xD;
          -  Temperature &gt;100.4°F at the time of enrollment.&#xD;
&#xD;
          -  Subjects undergoing treatment for tuberculosis infection or disease.&#xD;
&#xD;
          -  Having received any vaccinations or planned vaccinations with a live vaccine within 30&#xD;
             days prior or after study vaccination.&#xD;
&#xD;
          -  Having received any vaccinations or planned vaccinations with a killed vaccine within&#xD;
             14 days prior or after study vaccination.&#xD;
&#xD;
          -  Chronic administration of immuno-suppressant or immune-modifying drugs.&#xD;
&#xD;
          -  Post organ transplant subjects whether or not receiving chronic immunosuppressive&#xD;
             therapy.&#xD;
&#xD;
          -  Administration or planned administration of immunoglobulins and/or any blood products.&#xD;
&#xD;
          -  Use of any investigational or non-registered drug or vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Richard N Greenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-2859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St.Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt AIDS Clinical Trials Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 27, 2012</last_update_submitted>
  <last_update_submitted_qc>September 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

